# Albertsons Companies Inc. (ACI)

**Exchange:** NYSE  
**Coverage as of:** 2026-Q2  
**Updated:** 2026-05-27  
**Report type:** Primer (steps 1–3 of 19)  
**API endpoint:** GET /api/v1/research/ACI/primer

## Business Model

---
source: coverage-next-full
ticker: ACI
step: 01
title: Business Overview
created: 2026-05-27
---

### Step 01 — Business Overview: Albertsons Companies, Inc. (ACI)

#### 1. Company Description

Albertsons Companies, Inc. is the second-largest traditional supermarket operator in the United States [S1], operating 2,244 food and drug stores across 35 states and the District of Columbia as of February 28, 2026 [S2]. The company trades under 22 distinct regional banners — including Albertsons, Safeway, Vons, Jewel-Osco, Shaw's, Tom Thumb, Acme, and Randalls — and is headquartered in Boise, Idaho. ACI was formed through decades of grocery industry consolidation; it went public on the NYSE in June 2020 under the symbol ACI.

The business is fundamentally a **food and drug retailer**: customers purchase groceries, prepared foods, household goods, health and beauty products, and prescription medications through ACI's store network. Revenue in FY2026 (fiscal year ended February 28, 2026) was $83.2 billion, making ACI one of the largest food retailers in North America [S3].

#### 2. Value Chain Position

ACI operates in the **consumer-facing retail layer** of the food supply chain. It does not grow food or manufacture branded consumer goods at scale (though it does operate 19 manufacturing facilities for own-brand products). Its role is aggregation, distribution, and sale of food and consumer products to end consumers.

**Value-chain layer map:**

```
[Farm / CPG Manufacturer] → [Wholesale / Distributor] → [ACI Store Network] → [Consumer]
```

ACI's 22 dedicated distribution centers enable direct sourcing from manufacturers and selective bypassing of wholesale distributors, which improves margins on own-brand and perishable products [S4].

#### 3. Business Model

##### Three Revenue Pillars [S1, S4]

**1. Core Grocery & Fresh (est. ~85–87% of revenue)**
- Essential consumables (produce, meat, dairy, dry goods), household goods, health and beauty
- High transaction frequency — Americans shop grocery 1.6x per week on average
- Identical (same-store) sales growth was +2.0% in FY2026; digital sales +21%
- Own Brands (private label) at 26.5% penetration generating higher gross margins vs. national brands

**2. Pharmacy & Health (est. ~10–12% of revenue)**
- 1,713 in-store pharmacies as of FY2026
- Full-service pharmacy dispensing (prescription + OTC) + health services (immunizations, clinical)
- GLP-1 (weight-loss medication) prescription growth is a significant tailwind, driving pharmacy visits that convert to grocery purchases ("pharmacy halo effect")
- Headwind: IRA Medicare Drug Price Negotiation program begins compressing pharmacy revenue in FY2027 (~150bps headwind to identical sales per management guidance)

**3. Fuel, Convenience & Loyalty (est. ~3–5% of revenue)**
- 405 fuel center locations tied to loyalty points redemption
- "Albertsons for U" loyalty program: 51.2 million members as of Q4 FY2026 (+12% YoY) [S2]
- Loyalty platform powers personalized digital promotions and the Albertsons Media Collective (retail media network)
- Retail media: High-margin CPG advertising leveraging first-party data; quantum not separately disclosed but estimated in the $100–300M revenue range by analysts [S4]

##### Own Brands Portfolio [S1, S4]
- **Signature Select:** Core value-tier private label (grocery staples)
- **O Organics:** Premium organic line; one of the largest organic private label brands in the U.S.
- **Lucerne:** Dairy private label
- **Open Nature:** Natural/clean-label products
- **Chef's Counter:** Premium ready-to-eat meals (launched 2025)
- **Overjoyed:** Snack brand
- Target: 30% own brands penetration (vs. 26.5% today); every 100bps of penetration gain adds ~20–30bps gross margin

#### 4. Store Banner Geography

| Banner | Geography | Notes |
|--------|-----------|-------|
| Safeway | West Coast, Mid-Atlantic, Mountain | Large format; largest single banner by store count |
| Albertsons | Pacific Northwest, Idaho, Mountain West | Flagship banner |
| Vons / Pavilions | Southern California | Premium-positioned |
| Jewel-Osco | Chicago metro | Food + drugstore hybrid |
| Shaw's / Star Market | New England | Regional legacy |
| Tom Thumb / Randalls | Texas/Dallas-Fort Worth | |
| Acme | Mid-Atlantic (PA, NJ, DE, CT) | |
| United Supermarkets | West Texas / New Mexico | |
| Carrs | Alaska | |
| Haggen | Pacific Northwest | Limited stores |

ACI holds #1 or #2 market position in many of its 35 state footprints [S4]. Geographic concentration in West Coast (California especially) makes the business sensitive to California labor, regulatory, and competitive dynamics.

#### 5. Digital & Technology Strategy

- **Digital sales** grew 21% in FY2026 to approximately 9% of total grocery revenue [S2]
- **Albertsons for U** app: personalized deals, pharmacy management, grocery ordering
- **Omnichannel:** Click-and-collect (BOPIS) + home delivery; fulfillment primarily in-store (vs. dark store model)
- **AI pricing:** ACI uses AI-driven dynamic pricing and personalized promotions to compete on value without sacrificing margin across the board [S5]
- **Albertsons Media Collective:** Retail media network monetizing 51M loyalty members for CPG advertising spend; growing but undermonetized vs. Walmart Connect or Kroger Precision Marketing

#### 6. Customer Acquisition & Retention

- Transaction frequency: high-frequency, low-switching-cost environment (consumers shop weekly)
- Loyalty differentiation: "Albertsons for U" members spend significantly more per trip and are more digitally engaged
- Price competition: ACI competes on quality/freshness/private label differentiation rather than everyday low prices (EDLP) — positioning it mid-market vs. Aldi/Walmart

#### 7. Capital Intensity

- **Capex:** $1.8B in FY2026; guided $2.0–2.2B in FY2027 — heavy reinvestment, primarily remodels + new stores + digital [S2]
- **Store remodels:** 127 completed in FY2025; remodeled stores typically show 4–8% sales lift per management
- **Asset-light note:** ACI does NOT own most of its real estate; it predominantly leases (operating + finance leases). This explains the thin book equity relative to asset base.

#### 8. Post-Kroger Strategy: "Customers for Life"

Following the termination of the proposed Kroger merger in December 2024 [S6], ACI is executing as a standalone company under the "Customers for Life" strategic framework:
1. **Customer value proposition:** Sharpening price on key value items + driving own brands penetration
2. **Digital & loyalty acceleration:** Growing "for U" membership + monetizing via retail media
3. **Productivity:** $1.5B productivity plan through FY2025 to fund reinvestment
4. **Capital return:** $2.0B buyback authorization + growing dividend (13% increase to $0.68 annualized) [S2]
5. **Portfolio optimization:** Net closure of 26 stores in FY2026 (2,244 vs. 2,270 prior year); disciplined exit from underperforming markets

---

#### Source Index

| ID | Source | Reference |
|----|--------|-----------|
| S1 | FinancialContent/Finterra ACI Analysis (Apr 2026) | https://markets.financialcontent.com/stocks/article/finterra-2026-4-14-consolidation-and-continuity-a-deep-dive-into-albertsons-companies-inc-nyse-aci-in-2026 |
| S2 | ACI Q4/FY2026 Earnings Press Release | https://www.albertsonscompanies.com/newsroom/press-releases/news-details/2026/Albertsons-Companies-Inc--Reports-Fourth-Quarter-and-Full-Year-Results/default.aspx |
| S3 | SEC EDGAR XBRL Revenue Data | https://data.sec.gov/api/xbrl/companyfacts/CIK0001646972.json |
| S4 | ACI Industry/Competitive Analysis (web research) | ACI_financials/industry/competitive_landscape.md |
| S5 | FoodNavigator-USA — ACI Digital/AI Pricing | https://www.foodnavigator-usa.com/Article/2026/04/15/albertsons-uses-ai-pricing-to-offset-consumer-pullback/ |
| S6 | Kroger Merger Termination / Harvard Law Review | https://corpgov.law.harvard.edu/2025/01/21/practice-points-arising-from-albertsons-claims-against-kroger-for-breach-of-their-merger-agreement/ |

## Financial Snapshot

---
source: coverage-next-full
ticker: ACI
step: 04
title: Financial Quality
created: 2026-05-27
---

### Step 04 — Financial Quality: Albertsons Companies, Inc. (ACI)

#### 1. Statement Quality Overview

ACI reports under U.S. GAAP as an SEC-registered public company. Auditor is Deloitte & Touche LLP (continuously since at least 2020). No material weaknesses, restatements, or going concern qualifications in the filing history reviewed [S1].

**Key quality observation:** The largest GAAP vs. adjusted gap in ACI's history arises in FY2026 from the $773.8M opioid settlement charge. This is a genuine non-recurring, litigation-settlement obligation (disclosed since 2021; settled April 2026). The adjusted earnings ($2.18 EPS vs. $0.40 GAAP EPS) strip this out, which is analytically defensible — but investors should note the $482M NPV after-tax cash impact spread over 9 years is a real cost, not a free pass [S2].

---

#### 2. Statement-Quality Adjustments

##### Income Statement Adjustments

| Item | FY2026 Impact | Direction | Justification |
|------|--------------|-----------|--------------|
| Opioid settlement charge | $773.8M pre-tax ($600M after-tax) | Subtract from reported earnings | Non-recurring litigation reserve; settlement announced April 2026 [S2] |
| Merger-related legal/advisory costs | ~$50–100M (estimate; Kroger deal) | Subtract | One-time deal costs during merger process |
| CEO transition retention bonuses | ~$10M (estimate) | Subtract | One-time management change cost |

**Reported FY2026 GAAP Net Income:** $217M ($0.40/share)
**Adjusted Net Income:** $1,209M ($2.18/share)
**Difference:** $992M — the vast majority attributable to opioid settlement

##### Balance Sheet Adjustments

| Item | Impact | Notes |
|------|--------|-------|
| Goodwill + intangibles | ~$3.3B+ (estimate) | Result of decades of grocery M&A; drives negative tangible book value |
| Operating lease right-of-use assets | Substantial | ACI leases most stores; operating leases ~$6–7B estimated |
| Finance lease liabilities | Included in LT debt ($8.9B incl. finance leases) | True economic debt burden |
| Opioid settlement liability | Now on balance sheet as reserve | ~$774M booked Q4 FY2026 |

**Tangible book value/share: -$2.78 (FY2026)** — negative due to accumulated goodwill from historic acquisitions (Safeway 2015, United Supermarkets, etc.). This is typical for asset-light-property grocery chains with M&A history and does not represent insolvency risk [S3].

##### Cash Flow Quality
- **Operating cash flow** ($2,367M FY2026) significantly exceeds GAAP net income ($217M) — as expected for a retailer with large D&A + lease adjustments
- **Free cash flow** ($527M) declined substantially from FY2025 ($749M); primary driver is opioid settlement accrual timing and elevated capex
- FCF quality: REASONABLE. ACI has consistently generated positive FCF despite heavy capex ($1.6–2.1B/year). Working capital dynamics (negative, supplier-paid model) are structural free cash sources
- **D&A:** Estimated ~$2.8B/year based on EBITDA gap vs. operating income; supports book-earnings quality (D&A is real economic cost of store infrastructure)

---

#### 3. Revenue Recognition Quality

ACI's revenue recognition is standard retail — point-of-sale. No complex multi-element arrangements or significant deferred revenue. Key considerations:
- **Gift cards:** Recognized upon redemption or expiration (breakage)
- **Loyalty rewards:** Accounted for as performance obligations; deferred portion reduces revenue at point of sale
- **Fuel revenue:** Recorded on gross basis (significant for margin analysis; fuel has very low margins)
- **Pharmacy:** Revenue = drug cost + dispensing fee; prior authorization, DIR fees, and rebates create complexity but are standard pharmacy industry practice

**Assessment: Revenue recognition is straightforward and consistent with retail industry norms. No red flags.**

---

#### 4. Adversarial Research Sweep

*Per the full-research-gpt Step 04 spec, this section covers short reports, investigations, lawsuits, regulatory actions, and adversarial claims against ACI. Transcript analysis not performed (coverage-next-full path); sourced from press releases, SEC filings, and web research.*

##### 4.1 Opioid Litigation [MATERIAL — RESOLVED]
- **Claim:** ACI pharmacies improperly dispensed opioid prescriptions, contributing to the U.S. opioid epidemic
- **Status:** SETTLED — National settlement framework announced April 14, 2026: $773.8M over 9 years, covering nearly all state, local, and tribal government claims [S2]
- **Financial impact:** $773.8M pre-tax charge in Q4 FY2026; $482M estimated after-tax NPV; first payment April 30, 2026
- **Risk residual:** Some individual plaintiff claims may not be covered by the national framework; ongoing monitoring required
- **Assessment:** The largest known legal risk is now quantified and provisioned. Settlement is not an admission of liability.

##### 4.2 FTC Pricing Investigations
- **Claim:** In 2026, FTC/DOJ have been investigating grocery pricing practices industry-wide, including ACI
- **Status:** No enforcement action against ACI disclosed as of May 2026
- **Financial impact:** Unknown; not provisioned
- **Assessment:** Industry-wide regulatory risk. Material if enforcement leads to consent decree or fines, but not imminent [S4]

##### 4.3 Labor / Union Disputes
- **Claim:** Colorado labor strike (late 2025) — UFCW vs. ACI stores in Colorado
- **Status:** Resolved; strike ended in late 2025 per available information
- **Financial impact:** Modest revenue disruption during strike period; higher labor costs in settlement
- **Assessment:** Recurring risk — ACI renegotiates ~50–75 union contracts per year across 230,000+ unionized employees. Any single strike is manageable; pattern of escalating labor costs is a long-run margin headwind [S5]

##### 4.4 Kroger Merger Lawsuit
- **Claim:** ACI sued Kroger for $600M+ termination fee plus damages following Dec 2024 merger termination
- **Status:** Pending litigation
- **Counter-risk:** Kroger claims ACI's demands are "baseless"
- **Financial impact:** If ACI wins: $600M+ cash inflow (material positive). If ACI loses: no incremental cost (already incurred deal costs separately)
- **Assessment:** Binary upside optionality. Timeline uncertain (likely 12–24 months to resolution). Not in base case valuation [S6]

##### 4.5 Short-Seller / Bear Case Reports
- No prominent short reports specifically targeting ACI's accounting were found in research
- Primary bearish thesis is competitive/strategic (Aldi threat, margin compression) rather than accounting fraud
- **Assessment:** No material accounting fraud risk identified. ACI's financials are a legitimate business with thin margins, not a fabrication.

##### 4.6 Historical Accounting / Restatement
- No material restatements in ACI's SEC filing history (going back to 2017 when company began filing as Albertsons Companies, Inc. following predecessor reorganizations)
- **Assessment: Clean**

---

#### 5. Leverage & Interest Coverage Quality

| Metric | FY2026 | FY2025 | Assessment |
|--------|--------|--------|------------|
| Adj. EBITDA | $3,902M | $4,045M | — |
| Interest Expense (est.) | ~$600M | ~$500M | — |
| Interest Coverage (adj. EBITDA/Int.) | ~6.5x | ~8x | ADEQUATE |
| Net Debt / Adj. EBITDA | 2.24x | 2.24x | MANAGEABLE |
| Fixed Charge Coverage | — | — | Not directly available |

Interest coverage of ~6.5x is acceptable for investment-grade-adjacent corporate credit. ACI's debt is rated Ba1/BB+ (near investment grade) [S7]. The January 2026 refinancing eliminated 2027/2028 maturities, pushing next major maturities to 2031/2032/2034 — materially reducing near-term refinancing risk.

---

#### 6. Financial Quality Score

| Category | Score (1-5) | Notes |
|----------|------------|-------|
| Revenue recognition | 5 | Simple POS retail; no complex arrangements |
| Earnings quality (adj. vs. GAAP) | 3 | Large opioid gap is real cash cost; adjusted basis defensible |
| Cash flow generation | 4 | OCF >> net income; consistent FCF positive |
| Balance sheet transparency | 4 | Large lease obligations; disclosed clearly |
| Leverage management | 4 | 2.2x net debt/EBITDA; refinanced near-term maturities |
| Legal/regulatory clean bill | 3 | Opioid settled; pricing investigation + labor risk ongoing |
| **Overall** | **3.8 / 5** | **Adequate quality for investment-grade equivalent operation** |

---

#### Source Index

| ID | Source | Reference |
|----|--------|-----------|
| S1 | SEC EDGAR submissions (Deloitte auditor) | https://data.sec.gov/submissions/CIK0001646972.json |
| S2 | ACI Opioid Settlement Press Release (Apr 2026) | https://www.albertsonscompanies.com/newsroom/press-releases/news-details/2026/Albertsons-Companies-Announces-National-Opioid-Settlement-Framework/default.aspx |
| S3 | StockAnalysis.com Balance Sheet | https://stockanalysis.com/stocks/aci/financials/balance-sheet/ |
| S4 | Sahm Capital — ACI Pricing/Opioid Analysis (May 2026) | https://www.sahmcapital.com/news/content/should-opioid-settlement-and-pricing-lawsuit-pressures-require-action-from-albertsons-companies-aci-investors-2026-05-02 |
| S5 | Progressive Grocer — CEO Commentary | https://progressivegrocer.com/albertsons-ceo-looks-toward-year-ahead |
| S6 | Harvard Law / WISTV — Kroger Termination | https://corpgov.law.harvard.edu/2025/01/21/practice-points-arising-from-albertsons-claims-against-kroger-for-breach-of-their-merger-agreement/ |
| S7 | TipRanks — ACI Debt Refinancing | https://www.tipranks.com/news/company-announcements/albertsons-companies-issues-new-senior-notes-to-refinance-debt |

## Recent Catalysts

---
title: "Step 12 — Bull/Bear Catalysts"
ticker: ACI
company: Albertsons Companies, Inc.
source: coverage-next-full
created: 2026-05-27
---

### Step 12 — Bull/Bear Catalysts: Albertsons Companies, Inc. (ACI)

*Note: Earnings transcripts not loaded (coverage-next-full path). Analyst debate inferred from consensus notes, press releases, and recent filings.*

#### 1. Analytical Framework

The ACI debate centers on three core questions:
1. **Valuation reset:** Is the stock genuinely cheap at 4.3x EV/EBITDA, or does it deserve a structural discount to KR (~8x) due to Cerberus overhang, declining EBITDA, and regulatory risk?
2. **Pharmacy trajectory:** Does IRA/PBM pressure permanently impair pharmacy growth, or does volume growth (aging demographics, GLP-1) eventually overcome pricing headwinds?
3. **EBITDA stabilization:** Can Morris's "Customers for Life" strategy stabilize EBITDA at ~$3.85B+ (company guide), or is $3.5B the next floor as margin compression continues?

#### 2. Key Catalysts (Near-Term, 12 Months)

##### Positive Catalysts
1. **Pharmacy stabilization:** If Q1 FY2027 identical sales demonstrate pharmacy IRA headwind stabilization (vs. worsening), the stock likely re-rates from ~4.3x EV/EBITDA to 5.5–6.0x → ~25–35% upside
2. **EBITDA guidance beat:** If FY2027 adj. EBITDA comes in at $3.9B+ (vs. $3.875B midpoint), it signals floor-finding and restores guidance credibility
3. **Own brands acceleration:** Penetration moving from 25.7% to 26.5%+ in FY2027 adds ~$600M in higher-margin revenue, improving gross margins back toward 27.5%
4. **M&A premium / Cerberus exit:** Cerberus exploring strategic sale would assign a takeout premium (historical KR bid was 2x current price)
5. **Regulatory support for pharmacy:** If CMS moderates IRA implementation timeline, pharmacy reimbursement headwind reduces

##### Negative Catalysts
1. **Identical sales guidance cut below 0%:** If pharmacy pressure intensifies and food deflation hits simultaneously, ACI could report negative identical sales — significant earnings and multiple compression risk
2. **Capex discipline failure:** If FY2027 capex spends $2.2B and generates sub-2% EBITDA returns, FCF goes negative and dividend sustainability becomes questioned
3. **Cerberus strategic sale at depressed price:** If PE pressure forces a sale below intrinsic value, minority shareholders lose
4. **Further opioid litigation:** If settlement opt-in falls below threshold, new litigation risk emerges
5. **California labor cost escalation:** New legislation further compressing margins in the state representing ~20%+ of stores

#### 3. Street Debate Analysis (From Analyst Notes & Consensus)

##### Bull Case on Street (~11 Buy-rated analysts)
- ACI at 4.3x EBITDA is pricing in "grocery Armageddon that won't happen" — consensus
- Pharmacy volume growth (GLP-1, aging) provides long-term secular tailwind despite near-term IRA pricing noise
- Cerberus overhang is a free call option: worst case is standalone value; best case is acquisition premium
- $2B share repurchase authorization provides EPS support even if EBITDA is flat
- Morris is a known quality operator; strategy continuity reduces execution risk vs. new outsider CEO

##### Bear Case on Street (~8 Hold/Sell-rated analysts)
- EBITDA is in structural decline (FY2024: $4.1B → FY2026: $3.9B → FY2027 guide: $3.875B midpoint)
- Pharmacy headwind from IRA is "structural, not cyclical" — management said so; market isn't fully pricing it in
- Capex of $2.0–2.2B at peak while EBITDA declines = FCF destruction; dividend not sustainable at sub-$200M FCF
- Cerberus may use ACI as a vehicle for leverage rather than equity creation; management incentives not perfectly aligned with minority shareholders
- Walmart/Aldi are accelerating market share gains in ACI's core markets; identical sales will structurally underperform peers

#### 4. Thesis Tracker Update

| Thesis Element | Status | Confidence |
|---------------|--------|------------|
| Valuation is cheap (4.3x EBITDA) | CONFIRMED | High |
| Pharmacy as secular growth driver | CHALLENGED (IRA headwind) | Medium |
| Capital return (buybacks + dividend) | CONFIRMED | High |
| EBITDA stabilization | UNCERTAIN | Low-Medium |
| Cerberus alignment with minority shareholders | UNCERTAIN | Low-Medium |

---

#### Bull Case — 3 Bullets

• **Valuation reset from historic post-merger trough:** ACI trades at a >50% discount to grocery peers on EV/EBITDA (4.3x vs. KR 8x), pricing in permanent impairment that is overstated; as pharmacy IRA headwinds stabilize and management demonstrates FY2027 EBITDA delivery at $3.875B+, a re-rating to 5.5–6x would generate 25–40% total return from current levels plus a 4.2% dividend yield

• **Pharmacy + loyalty flywheel provides structural FCF floor:** 51.2M loyalty members (+12% YoY), $11.4B pharmacy revenue (with aging-demographics tailwind), and digital penetration above 10% create a customer-retention moat that sustains $2.3B+ in annual CFO — more than enough to fund the dividend ($340M) and meaningful buybacks even at elevated capex levels; at $16.30/share, investors are essentially buying $2.3B of annual cash generation for $8.1B

• **Cerberus optionality + buyback floor:** With $2B in repurchase authorization and Cerberus (26%) deeply motivated to realize value on a multi-decade grocery investment, the downside is cushioned — every $0.50 decline in stock price at current buyback pace removes ~1% of shares; any strategic transaction at even 6x EBITDA implies a $24+ stock (47% upside), suggesting the risk/reward skews materially bullish

---

#### Bear Case — 3 Bullets

• **EBITDA structural decline destroys the value proposition:** Adjusted EBITDA has declined from ~$4.1B (FY2024) to $3.9B (FY2026), with company guidance pointing to a $3.875B midpoint for FY2027 — a three-year declining trend that, combined with $2.0–2.2B capex, generates less than $200M in true FCF; if this trajectory continues (pharmacy IRA headwinds, labor cost escalation, Aldi/Walmart share erosion), ACI's dividend ($340M) is mathematically unsustainable, forcing an eventual dividend cut that would reprice the stock toward 3x EBITDA ($9–11/share)

• **Pharmacy is the thesis and pharmacy is breaking:** The single most important organic growth driver — pharmacy revenue growth from 8.7% to 13.7% of sales over 5 years — is now running into a structural wall from IRA drug price negotiation (which will cover 60+ drugs by 2029 and compounds each year), PBM reimbursement compression, and the possibility that GLP-1 drugs reduce food consumption (simultaneously hurting grocery volumes), leaving ACI with a pharmacy segment that is large, low-margin, and stagnating

• **Cerberus overhang prevents re-rating:** The market will not pay KR-comparable multiples (8x) for a company controlled by a PE firm with an uncertain exit timeline — Cerberus may pursue a strategic sale at the worst moment (market downturn), block organic investment in favor of leverage/distributions, or remain a governance distraction that limits institutional ownership expansion; the Cerberus discount is structural, not temporary, until the PE stake is substantially reduced

---

#### 5. Source Index
[S1] ACI Q4 FY2025 Earnings Release (April 2026) — guidance, pharmacy headwind commentary
[S2] ACI Q3 FY2026 Earnings Release (January 2026) — identical sales deceleration
[S3] StockAnalysis.com analyst consensus (19 analysts, May 2026)
[S4] GroceryDive, WebSearch — competitive dynamics, IRA analysis
[S5] ACI investor relations — "Customers for Life" strategic framework
[S6] FinancialContent / ainvest analysis — ACI 2026 bull/bear synthesis

## Full Research Available

This primer covers steps 1–3 of 19. The full deep dive (moat analysis, DCF, bull/bear,
management quality, earnings transcript analysis) is available via:

- Investment memo: /memo/aci
- Full research API: GET /api/v1/research/ACI/memo
- Coverage universe: /stocks